Financial Data and Key Metrics Changes - The company reported a 10% increase in total revenue year-over-year, with organic revenue growth of 3% [9] - Adjusted EBITDA for Q4 was $580 million, with adjusted EBITDA margins at 27.7% [9] - For the full year, adjusted EBITDA was approximately $2.1 billion, with an adjusted EBITDA margin of 27.4% [11] - Adjusted earnings per share for Q4 was $0.96, up 14% year-over-year, while for the full year it was $3.34, a 2% increase [10][11] - Free cash flow for Q4 was $462 million, with total liquidity at $3.8 billion [11] Business Line Data and Key Metrics Changes - In the ITS segment, orders increased by 9% in Q4, with revenue growth of 11% year-over-year [13] - The PST segment saw Q4 orders up 6% year-over-year, with organic orders up 1% [15] - Life science businesses within PST delivered mid-teens organic order growth [15] Market Data and Key Metrics Changes - The Americas region saw low single-digit organic order growth, while EMEA experienced a mid-single-digit decline, and Asia Pacific had low double-digit growth [14] - The company noted positive momentum in the life sciences market, particularly in pharma and biopharma production [25] Company Strategy and Development Direction - The company is focused on enhancing its existing portfolio through disciplined M&A, with a robust acquisition pipeline [6][7] - The recurring revenue initiative exceeded $450 million in 2025, with a backlog of approximately $1.1 billion [5] - The company aims for total revenue growth of 2.5% to 4.5% in 2026, driven by organic growth and M&A contributions [17] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improving trends in the market, particularly in life sciences and general industrial sectors [26] - The company remains agile and ready to adapt to changes in the global market landscape, emphasizing resilience and execution [20] - Management highlighted the importance of recurring revenue as a stable component of their business model [26] Other Important Information - The company completed 16 transactions in 2025, investing $525 million, which generated approximately $275 million in annualized inorganic revenue [7] - The Scinomix acquisition in January 2026 is expected to enhance the company's life science strategy [8] Q&A Session Summary Question: What sort of end market trajectory is embedded in the guidance? - Management indicated that the guidance assumes current market conditions continue, with no significant recovery embedded [24][30] Question: Are there any end markets that you're specifically worried about this year? - Management noted that headwinds from RNG, electric vehicles, and photovoltaics are largely behind them, with positive trends in China [30] Question: Can you provide clarity on the seasonality through the year? - Management expects Q1 organic growth to be flat or slightly down, with low single-digit growth anticipated for the rest of the year [34] Question: What are the expectations for cost actions or productivity gains during 2026? - Management confirmed that the guidance includes some productivity and cost actions, with proactive restructuring expected to yield savings [79] Question: Can you elaborate on the acquisition opportunity set? - Management stated that the current pipeline is primarily bolt-on in nature, with potential for larger acquisitions in the future [53] Question: What is the expected organic growth in the life sciences segment for 2026? - Management expressed optimism about continued momentum in life sciences, despite more challenging comps in 2026 [96]